Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 15/20 | 0.63 |
| ▸ | BRAF | P15056 | 1/20 | 0.59 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194083 | 1.00 | NFE2L2 (0.63) | NFE2L2BRAFGPR183PTGES2 | |
| SCHEMBL1194462 | 0.91 | NFE2L2 (0.61) | NFE2L2 | |
| SCHEMBL1194466 | 0.91 | NFE2L2 (0.61) | NFE2L2 | |
| SCHEMBL16828395 | 0.83 | NFE2L2 (0.60) | NFE2L2GPR183 | |
| SCHEMBL16828394 | 0.83 | NFE2L2 (0.60) | NFE2L2GPR183 | |
| SCHEMBL15511636 | 0.83 | TLR9 (0.60) | NFE2L2 | |
| SCHEMBL15497047 | 0.83 | TLR9 (0.60) | NFE2L2 | |
| SCHEMBL1195446 | 0.83 | NFE2L2 (0.53) | NFE2L2 | |
| SCHEMBL1195502 | 0.83 | TLR9 (0.60) | NFE2L2 | |
| SCHEMBL1195448 | 0.83 | NFE2L2 (0.53) | NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | claimed |
| US-20090247624-A1 | FORMULATIONS OF RADIOPROTECTIVE ALPHA BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-2046343-A2 | FORMULATIONS OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | Onconova Therapeutics, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| EP-1370253-B8 | USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY | UNIV TEMPLE (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2008105808-A2 | FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC. (US) | 2008-09-04 | — | — | WO | claimed |
| EP-1370253-B1 | USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY | UNIV TEMPLE (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1909775-A2 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | Onconova Therapeutics, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007016201-A2 | FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC. (US) | 2007-02-08 | — | — | WO | claimed |
| EP-1370253-A4 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH $g(a), $g(b) UNSATURATED ARYL SULFONES | UNIV TEMPLE (US) | 2005-08-17 | — | — | EP | claimed |
| US-6667346-B2 | Administration of a radioprotective alpha, beta unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces cytotoxic side effects of radiation on normal cells | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-23 | — | — | US | claimed |
| EP-1370253-A2 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH $g(a), $g(b) UNSATURATED ARYL SULFONES | Temple University of the Commonwealth System of Higher Education (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2002069892-A2 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-12 | — | — | WO | claimed |
| US-9713597-B2 | Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone | ONCONOVA THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20150265549-A1 | STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE | ONCONOVA THERAPEUTICS, INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-6667346-B2 | Administration of a radioprotective alpha, beta unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces cytotoxic side effects of radiation on normal cells | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-23 | — | — | US | disclosed |
| EP-1370253-A2 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH $g(a), $g(b) UNSATURATED ARYL SULFONES | Temple University of the Commonwealth System of Higher Education (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002069892-A2 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247624-A1 | FORMULATIONS OF RADIOPROTECTIVE ALPHA BETA UNSATURATED ARYL SULFONES | ARSA, DEGS1, AHR | NFE2L2 32/4885BRAF 2418/4885GPR183 1073/4885 |
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ARSA, SULT2A1, CYP2S1 | NFE2L2 37/4885BRAF 2710/4885GPR183 2226/4885 |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ARSA, AHR, SULT2A1 | NFE2L2 35/4885BRAF 2233/4885GPR183 1044/4885 |
| US-20150265549-A1 | STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE | TTPA, EBP, ADH1A | NFE2L2 334/4885BRAF 654/4885GPR183 1811/4885 |
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | DEGS1, ARSA, ABCE1 | NFE2L2 147/4885BRAF 2697/4885GPR183 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.